Cart
sales@molnova.com
β-Casomorphin (1-5), bovine
CAS No. 72122-63-5
β-Casomorphin (1-5), bovine ( —— )
Catalog No. M29964 CAS No. 72122-63-5
β-Casomorphin Fragment 1-5 (BCM5), an opioid receptor agonist, is a member of the β-casomorphin peptide family derived from β-casein. β-casomorphins are used to study their differential effects on processes such as hyperglycemia, oxidative stress, opioid signalling and immunosuppression.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product Nameβ-Casomorphin (1-5), bovine
-
NoteResearch use only, not for human use.
-
Brief Descriptionβ-Casomorphin Fragment 1-5 (BCM5), an opioid receptor agonist, is a member of the β-casomorphin peptide family derived from β-casein. β-casomorphins are used to study their differential effects on processes such as hyperglycemia, oxidative stress, opioid signalling and immunosuppression.
-
Descriptionβ-Casomorphin Fragment 1-5 (BCM5), an opioid receptor agonist, is a member of the β-casomorphin peptide family derived from β-casein. β-casomorphins are used to study their differential effects on processes such as hyperglycemia, oxidative stress, opioid signalling and immunosuppression.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number72122-63-5
-
Formula Weight579.64
-
Molecular FormulaC30H37N5O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Imeglimin hydrochlor...
Imeglimin hydrochloride prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.
-
Columbianetin beta-D...
Columbianetin-beta-D-glucopyranoside exhibits anti-inflammatory and analgesic properties, it also shows strong inhibiting activity against platelet aggregation.
-
Lumiracoxib
Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4.
